Sunstone
Sunstone Therapies Announces Publication of Long-term Benefits of Single-Dose Psilocybin in Depressed Patients with Cancer, in CANCER, the Journal of the American Cancer Society
June 16, 2025 | A new study conducted by Sunstone Therapies suggests that a single dose of psilocybin, combined with psychological support, can provide sustained relief from depression for some cancer patients.
Meet Dr. Manish Agrawal – Psychedelic Oncology Leader
Manish Agrawal, MD, brings an extensive academic, clinical, and research background and depth of experience to Sunstone.
Meet Kimberly Roddy – Psychedelic Therapy Co-Founder
Kimberly Roddy, MBA, Co-Founder and COO of Sunstone Therapies Kimberly Roddy is the Co-Founder and Chief Operations Officer of Sunstone […]
Psychedelic Alpha on Manish Agrawal and Kim Roddy, cofounders of Sunstone
Sunstone cofounders spoke with Josh Hardman about what they've learned from delivering hundreds of psychedelic therapy sessions.
Dr. Manish Agrawal Delivers Grand Rounds at Georgetown University Hospital
Psychedelic Medicine–History and Clinical Research January 30, 2025 Psychedelic Medicine: History and Clinical Research explores the resurgence of psychedelics in […]
Podcast: Perspectives on Psychedelic Research, Clinical Trials, and How We Can Continue To Connect With Heart
Manish Agrawal, MD joins Living Medicine host, Dr. Sandra Newes to discuss the challenges and future of psychedelic-assisted therapy research.
Podcast: A New Frontier of Psychedelic Therapies
Manish Agrawal, MD joins Power to the Patient host Brandon Li to discuss the transformative role of psychedelics in cancer care and mental health.
Medscape Medical News Feature: ‘Magic’ of Psychedelics, Easing the Trauma of Terminal Illness
September 12, 2022 | Recognizing the limitations of conventional oncology in addressing end-of-life psychological distress, Dr. Manish Agrawal and his team at Sunstone Therapies are advancing research into psilocybin-assisted therapy for patients with advanced cancer. In a recent clinical trial, a single psilocybin dose combined with group therapy resulted in a clinically significant reduction in depression symptoms for 80% of participants—highlighting the potential of psychedelic-assisted interventions to enhance quality of life and psychological well-being in palliative care settings.